Transcutaneous Electrical Nerve Stimulation (TENS) and Low Back Pain

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-60
SponsorUniversity of Hartford

About this trial

Low back pain is a significant public health problem, is very prevalent, and is often characterized by the persistence of symptoms. Unfortunately, substantial improvements in people with chronic low back pain are rare, causing most people to live with the pain. People with chronic low back pain may have an exaggerated pain response to nociceptive input into tissues that may also cause symptoms distant from the site of the primary symptoms. Historically, these symptoms were thought to be related to pathoanatomic changes to the muscles, ligaments, or joints. However, the severity of these structural changes weakly correlates with the clinical presentation and, in most cases, is not directly related to diagnostic image findings. Patients with chronic musculoskeletal pain, in general, show signs of local/central sensitization. The central sensitization may appear to be directly correlated with the intensity and duration of pain. Therefore, it is essential to reduce pain intensity and minimize the duration of pain to prevent this from happening.

Pain relief for chronic low back pain patients should be aimed at treatments that reduce central excitability and increase central inhibition. Research into chronic low back pain treatment has demonstrated strong evidence that different types of exercise decrease pain and improve quality of life. However, exercise itself may be painful, preventing a person from exercising. Thus, treatments aimed at decreasing pain will improve a person's ability to exercise and participate in activities of daily living.

One treatment aimed at reducing central excitability and increasing central inhibition is transcutaneous electrical nerve stimulation (TENS). TENS is a "non-pharmacological" treatment for pain that is inexpensive, safe, and easy to use. Prior studies show that TENS utilizes opioid receptors both spinally and supraspinally to inhibit nociceptive dorsal horn neurons, reduce excitatory neurotransmitter release, and reduce hyperalgesia. Thus, TENS may be particularly useful in people with chronic low back pain because it can activate descending inhibitory pathways (reduced in chronic low back pain patients) and inhibit central excitability (increased in chronic low back pain patients).

Previous studies that have investigated the effects of TENS on pain in low back pain patients have failed to use proper intensities of current, and the assessment of pain was not performed during the peak of the analgesic response. Previous studies show inadequate intensities do not reduce pain or increase pressure pain thresholds. Further, TENS typically does not affect resting pain, while changes in pressure pain thresholds and pain with movement are reduced. Thus, the current study proposes to assess the effects of TENS on measures of pain, function, and descending inhibition using the maximal tolerable intensity of TENS applied to a large area of the trunk.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

people who have experienced back pain for at least 3 months

and have reported a minimal pain level of 3 on the 0-10 Pain Numerical Rating Scale (NRS)

age from 18-60

TENS naive or have not used TENS for 5 years.

Disqualifiers

Serious spinal disorders, such as fractures, tumors, or inflammatory arthritis disease

nerve root disorders confirmed by neurological tests;

neurological diseases

severe cardiorespiratory disease

Trial design

Design model

Crossover

Treatments tested in this trial

  • TENS

    Device

    Active TENS

Treatment groups

34 Participants
are divided into 3 treatment groups
Group A: Active TENSExperimental treatment 1 intervention
Group B: Placebo TENSPlacebo comparator 1 intervention
Group C: No TENSNo intervention 0 interventions

Trial outcomes

Primary outcomes

1

Pain at Rest

Pain at Rest Difference Score Pre-intervention and Post Intervention measured by the Numeric Pain Rating Scale. It starts with the absence of pain (0) and reaches the worst pain imaginable (10).

Time frame
3 weeks
2

Pain With Movement

Pain With Movement Difference Score Pre-intervention and Post Intervention measured by the Numeric Pain Rating Scale. It starts with the absence of pain (0) and reaches the worst pain imaginable (10).

Time frame
3 weeks

Secondary outcomes

1

Sit-to-Stand Test

Five sit-to-stand repetitions will be completed in two trials with an average of two trials for scoring

Time frame
3 weeks
2

Repeated trunk flexion

From a neutral standing position, the subject will be required to flex to the limit of the range and return to the upright position as fast as tolerable.This activity will be repeated 10 times, and the total procedure will be timed with a stopwatch

Time frame
3 weeks
3

Pressure Pain Threshold (PPT)

A digital pressure algometer will measure the pain threshold to deep mechanical stimuli.

Time frame
3 weeks
4

Heat Pain Threshold (HPT)

Superficial heat pain sensitivity will be assessed using a handheld thermode.

Time frame
3 weeks

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.